79th World Health Assembly (WHA79): Draft updated global action plan on antimicrobial resistance
We welcome the timely update of the Global Action Plan on AMR (GAP), which provides a unique opportunity to take stock of progress to date and redouble efforts in addressing gaps ahead of the planned 2029 UN AMR HLM. We are broadly supportive of the proposed strategic objectives and reiterate the urgent need to advance effective R&D incentives for antibiotics to address the growing burden of resistant infections. At the same time, we call on governments to work with industry in advancing sustainable access for antibiotics across different contexts, firmly grounded in a collaborative approach, including prioritizing the principle of VMAT for technology transfer.
IFPMA has maintained long-standing commitment to the issue of AMR, including through establishing and leading the AMR Industry Alliance, and the innovative pharmaceutical industry has continued to advance R&D through the IFPMA BCR AMR Action Fund. We stand ready to work with governments and other partners in advancing sustainable long-term solutions and contributing our sector’s unique expertise, including in relation to the upcoming Independent Panel on Evidence for Action against AMR (IPEA).
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
158th session of the WHO Executive Board (EB158): Draft updated global action plan on antimicrobial resistance
On 4 February 2026, IFPMA delivered a statement on Agenda item 14 on the draft updated global action plan on antimicrobial resistance (AMR) at the 158th session of the WHO Executive Board. We welcome the timely update of the Global Action Plan on AMR (GAP), which provides a unique opportunity to take stock of progress...
Read moreRevitalizing the antibiotic pipeline by implementing new R&D pull incentives
With the 2024 UN High-Level Meeting on antimicrobial resistance (AMR) and its political declaration, together with the biennial AMR Ministerial Meeting, the world has set an ambitious agenda to tackle AMR. The next four years offer renewed political momentum to deliver progress ahead of the next UN High-Level Meeting on AMR in 2029. A central priority is creating the necessary policy frameworks that stimulate R&D investment. This brief identifies the key barriers to antibiotic R&D and the policy measures needed to address them. Sustainable, effective pull incentives are urgently required to ensure a reliable pipeline of new antibiotics for patients and health systems. We set out how these incentives should be designed and implemented, guided by a set of core principles to maximize their impact.
Read more
Open letter from the innovative pharmaceutical industry to G7 leaders
Ahead of the G7 Leaders’ Summit in Kananaskis from 15 to 17 2025, the global pharmaceutical industry, represented by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Innovative Medicines Canada (IMC), are calling on G7 governments to place health and innovation at the top of their agenda.
Read more